C3N-00579
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 67.77549624
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.510
- INTERFERON_GAMMA_RESPONSE+0.450
- E2F_TARGETS+0.440
- DNA_REPAIR+0.290
- G2M_CHECKPOINT+0.290
- OXIDATIVE_PHOSPHORYLATION+0.260
- HEME_METABOLISM+0.250
- ALLOGRAFT_REJECTION+0.200
- UV_RESPONSE_UP+0.160
- SPERMATOGENESIS+0.140
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- HEDGEHOG_SIGNALING-0.310
- WNT_BETA_CATENIN_SIGNALING-0.300
- APICAL_JUNCTION-0.290
- KRAS_SIGNALING_DN-0.280
- PANCREAS_BETA_CELLS-0.240
- HYPOXIA-0.230
- UV_RESPONSE_DN-0.220
- APICAL_SURFACE-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202424 | — | — | 0.861 |
| 2 | TCGA-BB-A6UM-01A-12R-A34R-07 | — | — | 0.853 |
| 3 | TCGA-80-5611-01A-01R-1628-07 | — | cohortA4 | 0.830 |
| 4 | SRR26320066 | — | — | 0.825 |
| 5 | TCGA-CV-6433-01A-11R-1686-07 | — | — | 0.823 |
| 6 | SRR12202422 | — | — | 0.819 |
| 7 | b652254e-228b-40d4-be79-536ad87dad69 | — | — | 0.819 |
| 8 | SRR12202423 | — | — | 0.816 |
| 9 | TCGA-05-4397-01A-01R-1206-07 | — | cohortA4 | 0.811 |
| 10 | ULC0583T_S75 | — | cohortA1 | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.250 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.050 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |